Diurnal modulation of subthalamic beta oscillatory power in Parkinson’s disease patients during deep brain stimulation

Abstract

Beta-band activity in the subthalamic local field potential (LFP) is correlated with Parkinson’s disease (PD) symptom severity and is the therapeutic target of deep brain stimulation (DBS). While beta fluctuations in PD patients are well characterized on shorter timescales, it is not known how beta activity evolves around the diurnal cycle, outside a clinical setting. Here, we obtained chronic recordings (34 ± 13 days) of subthalamic beta power in PD patients implanted with the Percept DBS device during high-frequency DBS and analysed their diurnal properties as well as sensitivity to artifacts. Time of day explained 41 ± 9% of the variance in beta power (p < 0.001 in all patients), with increased beta during the day and reduced beta at night. Certain movements affected LFP quality, which may have contributed to diurnal patterns in some patients. Future DBS algorithms may benefit from taking such diurnal and artifactual fluctuations in beta power into account.

The aperiodic exponent of subthalamic field potentials reflects excitation/inhibition balance in Parkinsonism: a cross-species study in vivo

“…Second, we observed medication-related changes of the aperiodic exponent in hemispheres without clear beta peaks or medication-related beta changes. Third, we estimate the aperiodic exponent between 40 and 90 Hz, when studying the effect of levodopa, avoiding lower frequencies, which are particularly susceptible to movement-related artefacts (van Rheede et al, 2022).…”

Christmas‐Related Reduction in Beta Activity in Parkinson's Disease

“…Chronic sensing was set up as previously described. 9 In one case (sub-014) sensing was activated only in the right hemisphere. This has led to the availability of brain signal recordings from seven STNs in 4 patients, with a mean peak frequency of 18.8 AE 6 Hz.…”

“…All participants provided written informed consent. 9 The study was approved by the local ethics committee of the Charité -Universitätsmedizin Berlin (EA2/256/ 60) and conducted in accordance with the ethical standards set by the Declaration of Helsinki. The inclusion criterion for the retrospective study was the availability of at least 22 days of chronic brain signal recordings starting from December 10 to January 1.…”

Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation

“…In the US, EU and Canada the ADAPT PD approval trial (NCT04547712) evaluating aDBS has completed enrollment. In Japan, where aDBS is approved, early case study results are promising (Nakajima et al, 2021;Kimura et al, 2022;van Rheede et al, 2022) and continue to build upon the evidence for patient benefit suggested by previous investigational pilots (Little et al, 2013;Arlotti et al, 2018;Velisar et al, 2019). Finally, several physiciansponsored NIH BRAIN Initiative trials are applying the Summit TM RC + S to investigate new indications including treatment resistant depression, Tourette's syndrome and opioid use disorder.…”

“…Moreover, studies across multiple centers demonstrate the capability of Percept ™ PC to routinely detect LFP signals of interest in PD, ET, dystonia, OCD and epilepsy subjects with standard of care procedures ( Fasano et al, 2021 ; Goyal et al, 2021 ; Thenaisie et al, 2021 ; Buijink et al, 2022 ; Vissani et al, 2022 ), which is also consistent with prior studies using investigational recording devices ( Case et al, 2020 ; Darcy et al, 2022 ). Further, there is a growing body of case studies demonstrating the application of brain sensing for personalized treatment including initial DBS programming ( Fasano et al, 2021 ; Sirica et al, 2021 ), DBS and medication optimization ( Kern et al, 2022 ), and even understanding circadian patterns ( van Rheede et al, 2022 ).…”